Becton Dickinson (BDX)

Becton Dickinson (BDX) has undergone significant structural changes, having recently spun off its life sciences business and merged it with Waters Corporation, thereby positioning itself as a pure-play medical technology company. This transformation aims to focus on higher-growth and higher-margin areas within the medical sector. Despite management's previous projections of $15 EPS, the new guidance suggests a more conservative estimate of $12.50 for 2026, while expectations for operating margins have risen from 21% to 25%. The stock is currently considered attractively priced at 14x earnings, but there are inherent risks associated with the ongoing changes. Furthermore, analysts have set a price target of $200.00, indicating a cautiously optimistic outlook. However, concerns remain regarding the macroeconomic environment, particularly given BDX's strong ties to hospital systems, which has caused some experts to adopt a wait-and-see approach before re-evaluating their investment stance.